期刊文献+

宫颈癌的靶向药物治疗研究进展 被引量:3

Progress of Targeted Drug Therapy for Cervical Cancer
在线阅读 下载PDF
导出
摘要 宫颈癌是妇科最常见恶性肿瘤之一,随着分子生物学的发展,在局部晚期宫颈癌患者的治疗中的靶向治疗药物不断涌现。宫颈癌的靶向治疗已经成为目前研究的热点。本文对宫颈癌的靶向药物治疗研究进展作一综述,为指导宫颈癌临床用药提供基础。 Cervical cancer was one of the most common gynecologic cancer. With the development of molecular biology, the targeted drugs for patients of locally advanced cervical cancer continued to emerge. The targeted drug treatment of cervical cancer had become a hot research. This article reviewed the progress of the targeted drug treatment for patients of cervical cancer, and provided the basis for the clinical medication.
出处 《国外医药(抗生素分册)》 CAS 2015年第4期154-156,183,共4页 World Notes on Antibiotics
基金 陕西省自然科学基础研究计划项目(2014JQ2-8055) 陕西省教育厅专项科研计划项目(14JK1622) 西安医学院校级科研计划扶植项目(12FZ16)
关键词 宫颈癌 靶向药物 进展 cervical cancer targeted drug progress
作者简介 甘露,博士,主治医师,研究方向:从事妇科肿瘤及生殖内分泌研究。
  • 相关文献

参考文献20

  • 1Olsen AH, Parkin DM, Sasieni P. cancer mortality in the united kingdom : projections to the year 2025[J]. Br J cancer, 2008, 99(9): 1549-1554.
  • 2Shi JF, Canfell K, Lew JB, et al. The burden of cervical cancer in china synthesis of the evidence[J], cancer, 2012, 130(3): 641-652.
  • 3邓克红,王晨阳,王武亮.西妥昔单抗联合奈达铂对宫颈癌Hela细胞增殖的影响[J].郑州大学学报(医学版),2014,49(1):99-102. 被引量:5
  • 4Santin AD, Sill MW, Mcmeekin DS, et al. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2011,122(3): 495-500.
  • 5Farley J, Sil MW, Birrer M, et al. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2011, 121(2): 303-308.
  • 6Goncalves A, Fabb ro M, Lhomm6 C, et al. A phase II trial to evaluate gefitinib as second - or third -line treatment inpatient s with recurring locoregionally advanced or metastaticcervi cal cancer.[J]. Gynecol Oncol, 2008, 108 (1):42 -46.
  • 7Sharma DN, Rath GK, Julka PK, et al. Role of gefitinib in patients with recurrent or metastatic cervical carcinoma ineligible or refractory to systemic chemotherapy: first study from Asia[J]. Int J Gynecol Cancer, 2013, 23(4):705-709.
  • 8Kummel S, H eidecke H, Brock B, et al. Imatiniba possible therapeutic option for cervical carcinoma:results of a preclinical phase I study[J].Gynakol Geburtshilfliche Runds oh, 2008.48:94 -100.
  • 9Candelaria M, Arias-Bonfill D, Chvez-Blanco A, et al. Lack in efficacy for imatinib mesylate as second- line treatment of recurrent or metastatic cervical cancer expressing platelet-derived growth factor receptor alpha[J]. Int J Gynecol Cancer, 2009, 19(9): 1632-1637.
  • 10Dai Q, Ling YH, Lia M, et al. Enhanced sensitivity to the H ER1/epidermal grow th factor receptort yrosine kinase inhibitor erlotinib hydrochloride in chemotherapy -resistanttumor cell lines[J].Clin Cancer Res, 2005, 11:1572 - 1578.

二级参考文献11

  • 1薛琴琴,张菊,俞青苗,金雯,杨梅,刘宁侠,高艳娥.宫颈癌组织表皮生长因子受体对TKI敏感性相关的基因突变研究[J].西安交通大学学报(医学版),2012,33(5):583-586. 被引量:5
  • 2王利娟,田园,高积勇.宫颈癌预后与表皮生长因子受体蛋白表达关系[J].中国妇幼健康研究,2006,17(4):280-282. 被引量:6
  • 3吴仁瑞,吴少雄,赵充,谢方云,高剑铭,胡伟汉,高远红,李凤岩,崔甜甜,卢泰祥.h-R3联合放疗治疗局部晚期鼻咽癌的Ⅱ期临床研究[J].癌症,2007,26(8):874-879. 被引量:24
  • 4Kim SJ,Rabbani ZN,Dong F. Phosphorylated epider-mal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer[J].{H}MEDICAL ONCOLOGY,2010,(1):91.
  • 5Ettinger DS. Clinical implications of EGFR expression in the development and progression of solid tumors:focus on non-small cell lung cancer[J].{H}Oncologist(the)t,2006,(4):358.
  • 6Harari PM. Epidermal growth factor receptor inhibition strat-egies in oncology[J].{H}Endocrine Related Cancer,2004,(4):689.
  • 7Koshiyama M,Kinezaki M,Uchida T. Chemosensitivi-ty testing of a novel platinum analog,nedaplatin (254-S),in human gynecological carcinomas:a comparison with cis-platin[J].{H}Anticancer Research,2005,(6C):4499.
  • 8Desoize B,Madoulet C. Particular aspects of platinum com-pounds used at present in cancer treatment[J].{H}Critical Reviews in Oncology/Hematology,2002,(3):317.
  • 9Bowers G,Reardon D,Hewitt T. The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal trans-duction responses of human carcinoma cells[J].Onco-gene,2001,(11):1388.
  • 10王海荣,于长华,朱卫国,李涛.奈达铂与顺铂在宫颈癌同步放化疗中的应用[J].实用妇产科杂志,2011,27(10):771-774. 被引量:18

共引文献4

同被引文献21

引证文献3

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部